多医院社区健康系统实施万古霉素AUC治疗药物监测的程序性变化评估
该回顾性准实验研究纳入150例患者(每组75例),比较谷浓度监测与AUC监测万古霉素的临床和操作结局。AUC组达到治疗目标的中位时间显著更短(38小时 vs 62小时,P<0.01),首次稳态达标率更高(66.7% vs 22.7%,P<0.01),且剂量调整次数更少(中位1次 vs 1次,P<0.01)。两组在万古霉素疗程、平均日剂量或急性肾损伤方面无显著差异。
要点
- AUC监测组达治疗目标中位时间38小时,显著短于谷浓度组的62小时(P<0.01)。
- AUC组首次稳态达标率66.7%,显著高于谷浓度组的22.7%(P<0.01)。
- AUC组剂量调整次数中位1次(IQR 0.0-1.0),少于谷浓度组的1次(IQR 1.0-2.0)(P<0.01)。
核心结论
- 在社区健康系统中实施基于AUC的万古霉素监测可更快达到治疗目标且剂量调整更少,提示可能改善临床效率。
研究设计与样本
- 回顾性准实验研究,纳入150例患者(每组75例),比较谷浓度监测组与AUC监测组。
- 两组患者特征相似:63%男性,平均年龄60岁,常见适应症为菌血症、肺炎和骨髓炎。
主要发现
- AUC组达到治疗目标的中位时间显著短于谷浓度组(38小时 vs 62小时,P<0.01)。
- AUC组首次稳态达标率显著高于谷浓度组(66.7% vs 22.7%,P<0.01)。
- 两组在万古霉素疗程、平均日剂量或急性肾损伤方面无显著差异。
- AUC组剂量调整次数中位1次(IQR 0.0-1.0),少于谷浓度组的1次(IQR 1.0-2.0)(P<0.01)。
关键数值与推荐
- AUC监测组治疗目标定义为AUC/MIC比值400至600。
- 谷浓度监测组治疗目标定义为谷浓度15-20 µg/mL。
临床怎么用
- 临床可考虑实施基于AUC的万古霉素治疗药物监测以更快达标并减少剂量调整。
- 需进一步研究直接评估AUC监测对患者结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Therapeutic drug monitoring (TDM) of vancomycin using the ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) is recommended but poses practical challenges. Our community health system implemented AUC-based vancomycin monitoring in 2020 and aimed to assess its impact on clinical and operational outcomes. METHODS: This retrospective, quasi-experimental study included 2 arms: trough-based monitoring and AUC-based monitoring. The primary outcome was the time to attainment of the therapeutic target, defined as attainment of an AUC/MIC ratio of 400 to 600 for the AUC-based monitoring arm or attainment of a trough concentration of 15-20 µg/mL for the trough-based monitoring arm. Additional endpoints included treatment failure, vancomycin dose, dose adjustments, and acute kidney injury (AKI). RESULTS: A total of 150 patients (75 per arm) were included, with similar characteristics in both groups: 63% male, average age of 60 years, and common indications of bacteremia, pneumonia, and osteomyelitis. The AUC-based monitoring arm had significantly faster therapeutic target attainment (median, 38 hours vs 62 hours; P < 0.01) and a higher rate of target attainment at first steady-state levels (66.7% vs 22.7%, P < 0.01). No significant differences were observed in vancomycin duration, average daily dose, or AKI. AUC-based vancomycin monitoring resulted in more rapid therapeutic target attainment when compared to trough-based monitoring, resulting in fewer dose adjustments (median, 1 [IQR, 0.0-1.0] vs 1 [IQR, 1.0-2.0]; P < 0.01). CONCLUSION: The implementation of AUC-based vancomycin monitoring in our community health system led to faster attainment of therapeutic targets, with fewer dose adjustments, suggesting potential for improved clinical efficiency. Further studies are needed to directly assess the impact on patient outcomes.
引用
- Morton S, Cubillos A, Saunders MB, et al. Implementation of vancomycin area under the curve therapeutic drug monitoring: Evaluation of procedural changes at a multihospital community health system. Am J Health Syst Pharm. 2026. PMID: 41126453. doi:10.1093/ajhp/zxaf289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。